Evaluating the diagnostic performance of <sup>18</sup>F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.
Authors: Rupesh Kotecha, Veronica Chiang, Martin C Tom, Ali Nabavizadeh, Elcin Zan, Srinivas Peddi, Erik P. Sulman, Barry A. Siegel, Jiayi Huang, Steven Brem, Marcus Ware, Santosh Kesari, Ephraim E. Parent, Whitney B. Pope, Robin Holmes, Albert Chau, Eugene J. Teoh, Samuel T. Chao, Mariam Aboian
Journal: Journal of Clinical Oncology (2023)

2001 Background: Differentiating radiation necrosis from tumor progression remains one of the most commonly encountered and clinically challenging scenarios after radiation therapy (RT) for brain metastases (BM). PURSUE (NCT04410367) evaluated the diagnostic performance of 18 F-fluciclovine, an amino acid PET radiopharmaceutical, based on various lesion metrics, to establish image interpretation criteria (IIC) for suspected recurrent BM after RT. Methods: Patients with solid tumor BM were enrolled across 7 US sites if they had a previously irradiated ‘reference’ lesion equivocal on MRI for recurrence and were planned for craniotomy. 18 F-Fluciclovine PET (185 MBq) took place &lt;42 days post-MRI and 1-21 days pre-craniotomy. The primary endpoint was the diagnostic performance (sensitivity, specificity, positive-, and negative-predictive value [PPV/NPV]) of different thresholds of lesion 18 F-fluciclovine uptake on qualitative, visual reads vs central histopathological analysis. Lesion 18 F-fluciclovine uptake was assessed qualitatively by 3 independent blinded readers who visually rated the uptake as ‘mild’ (up to blood pool), ‘moderate’ (above blood pool to parotid), or ‘marked’ (above parotid). Secondary endpoints included the diagnostic performance based on different thresholds of quantitative (e.g., lesion SUV) and dynamic measures of uptake. A committee, including 2 expert imaging physicians independent to PURSUE, reviewed all data in round-table meetings to establish the IIC, which were subsequently used to assess diagnostic performance. Results: All 23 reference lesions in 23 subjects underwent histopathological analysis, with 10 (43%) confirmed as recurrent tumor. The highest performing qualitative measure was ‘marked’, rendering a sensitivity of 92-100%, with variable specificity of 40-80% across readers. SUV max was a reader-independent, high-performing quantitative metric on ROC analysis (AUC 0.87, SUV max threshold 4.8 conferring a sensitivity of 80% and specificity of 85%). Dynamic measures did not provide added diagnostic value. After analyzing these metrics, the committee established IIC as: Lesions with 18 F-fluciclovine uptake of a SUV max equal to or greater than 4.8, or visually greater than the parotid gland, should be considered suspicious for recurrence. Otherwise, recurrence should be considered unlikely. Application of the IIC resulted in a sensitivity of 80%, specificity of 77-85%, PPV of 73-80%, and NPV of 83-85% across the readers. Conclusions: This is the first prospective multicenter trial to evaluate PET characteristics of suspected recurrent BM after RT, verified by histopathology. Qualitative and quantitative IIC show 18 F-fluciclovine to be a high-performing diagnostic tool. These IIC will help evaluate the diagnostic performance of 18 F-fluciclovine PET in future trials. Clinical trial information: NCT04410367 .